Effect of post-storage filters vs. pre-storage filters for leukoreduction of blood components on clinical outcomes: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
1
6
2021
medline:
3
11
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
This review will synthesize the best available evidence on the effectiveness of leukocyte reduction by comparing post-storage and pre-storage filters. The review will consider the following clinical outcomes: transfusion reactions, bacterial infection, length of stay, and mortality. Transfusion is a relevant therapy, but it is not risk-free. Leukocyte reduction can be performed either by apheresis or by pre- or post-storage filters in order to reduce the risk of transfusion reactions, transmission of some diseases, alloimmunization, and platelet refractoriness. It can also reduce the length of hospital stay and the use of antibiotics. Studies comparing the transfusion of leukocyte reduction through post-storage filters with pre-storage filters in patients of any age who received a transfusion and the clinical outcomes resulting from the transfusion will be considered for inclusion. Studies in Portuguese, English, and Spanish will be considered, with no publication time limit. The research sources will include MEDLINE (PubMed), CINAHL (EBSCO), PsycINFO, Scopus, The Cochrane Library, Web of Science Core Collection, Embase, LILACS, and gray literature sources. The selection of titles and abstracts will be carried out by two independent reviewers, and the critical evaluation of the studies will be based on JBI tools. The data of interest for the review question will be extracted using JBI SUMARI. A narrative synthesis will be performed as will a meta-analysis and risk assessment of publication bias, if possible. PROSPERO: CRD42020192202.
Identifiants
pubmed: 34054033
doi: 10.11124/JBIES-20-00353
pii: 02174543-202109000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2382-2388Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Tobian AAR, Heddle NM, Wiegmann TL, Carson JL. Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion 2016; 56 (10):2627–2630.
Brasil. Ministério da Saúde. Portaria n° 158, de 4 de fevereiro de 2016. [Redefining the technical regulation of blood therapy procedures] [internet]. Diário Oficial da União, Brasília. 2016 [cited 2020 Feb 20]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2016/prt0158_04_02_2016.html . [Portuguese]
Carson JL, Gyyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 16 (19):2025–2035.
Fung MK, editor. Technical manual. 19th ed. Technical manual. Bethesda, MD: American Association of Blood Banks, 2017.
Kunkel SL. Davenport RD, Sinyder EL. An introduction to cytokine biology. AABB Press, Cytokines in transfusion medicine: a primer . Bethesda, MD: 1997.
World Health Organization. WHO guidelines on good manufacturing practices for blood establishments [internet]. Geneva; 2011 [cited 2020 Jun 17]. Available from: https://www.who.int/bloodproducts/publications/GMP_Bloodestablishments.pdf?ua=1 .
Agence Nationale de Sécurité du Médicament et des Produits de Santé. [2013 Haemovigilance activity report] [internet]. Saint-Denis. 2014 [cited 2020 Jun 17]. Available from: http://hemovigilance-cncrh.fr/www2/votre_region/rhone-alpes/rapport_d_activite_ra_2013.pdf . [French]
Politis C, Wiersum JC, Richardson C, Robillard P, Jorgensen J, Renaudier P, et al. The international haemovigilance network database for the surveillance of adverse reactions and events in donors and recipients of blood components: technical issues and results. Vox Sang 2016; 111 (4):409–417.
Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2015; 55 (4):709–718.
Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, et al. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual center experience. Transfus Med 2015; 25 (6):418–423.
Lannan K, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation—the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis 2013; 50 (1):61–68.
Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2011; 115 (3):635–649.
Alberti LR, Vasconcellos LS, Petroianus A. Influence of blood transfusion on development of infection in patients with malignant neoplasms of the digestive system. Arq Gastroenterol 2006; 43 (3):168–172.
Agência Nacional de Vigilância Sanitária. Resolução RDC n. 34, de 11 de junho de 2014. [Guidelines for good practice in the blood cycle] [internet]. Diário Oficial da União, Brasília. 2014 [cited 2020 Feb 20]. Available from: https://saude.rs.gov.br/upload/arquivos/carga20170553/04145350-rdc-anvisa-34-2014.pdf . [Portuguese]
Paula GG, Novaretti MC, Pozzi DHB, Chamone DAF. Study of the platelet refractoriness in patients submitted to bone marrow transplant from day 0 to day 50. Rev Bras Hematol Hemoter 2004; 26 (1):3–12.
Hébert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289 (15):1941–1949.
Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43 (11):1545–1552.
Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, et al. Patient and product factors affecting platelet transfusion results. Transfusion 2008; 48 (4):681–687.
Vamvakas EC. The abandoned controversy surrounding universal white blood cell reduction. Blood Transfus 2014; 12 (2):143–145.
Wang RR, Triulzi DJ, Qu L. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets. Am J Clin Path 2012; 138 (2):255–259.
Da Ponte A, Bidoli E, Talamini R, Steffan A, Abbruzzese L, Toffola RT, et al. Pre-storage leucocyte depletion and transfusion reaction rates in cancer patients. Transfus Med 2005; 15 (1):37–43.
Garancini M, Degrate L, Carpinelli MR, Maternini M, Uggeri F, Giordano L, et al. Impact of pre-storage and bedside filtered leukocyte-depleted blood transfusions on infective morbidity after colorectal resection: a single-center analysis of 437 patients. Surg Infect 2013; 14 (4):374–380.
Mishima Y, Tsuno NH, Matsuhashi M, Yoshizato T, Sato T, Ikeda T, et al. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness. Transfus Apher Sci 2015; 52 (1):112–121.
Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41 (8):997–1000.
Simancas-Racines D, Osorio D, Martí-Carvajal AJ, Arevalo-Rodriguez I. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database Syst Rev 2015; 12:CD009745.
Simancas-Racines D, Arevalo-Rodriguez I, Urrutia G, Buitrago-Garcia D, Núñez-González S, Martínez-Zapata MJ, et al. Leukodepleted packed red blood cells transfusion in patients undergoing major cardiovascular surgical procedure: systematic review and meta-analysis. Cardiol Res Pract 2019; 2019:7543917.
Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis (formerly JBI Reviewer's Manual) [internet]. Adelaide: JBI; 2017 [cited 2020 Jun 14]. Available from: https://synthesismanual.jbi.global .
Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (7):e1000097.
Grade Working Group. The Grading of Recommendations Assessment, Development and Evaluation [internet]. 2004-2020 [cited 2020 Jun 17]. Available from: http://www.gradeworkinggroup.org/ .
Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 2015; 13 (3):196–207.